(thirdQuint)Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia.

 OBJECTIVES: - Determine the response rate in pediatric patients with relapsed or refractory acute lymphoblastic or acute myeloid leukemia treated with docetaxel.

 - Determine the toxicity of this regimen in these patients.

 OUTLINE: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15.

 Treatment repeats every 28 days for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A total of 10-20 patients will be accrued for this study within 1 year.

.

 Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia@highlight

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop cancer cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating children who have relapsed or refractory acute lymphoblastic or acute myeloid leukemia.

